Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Medical System Holdings ( (HK:0867) ) just unveiled an update.
China Medical System Holdings announced that its subsidiary, Dermavon Holdings, has obtained licensing rights for the innovative oral JAK 1 inhibitor, povorcitinib, which has been included in China’s list of Breakthrough Therapeutic Drugs. This inclusion is expected to accelerate the drug’s development and review process, potentially offering a new treatment option for non-segmental vitiligo patients in China. The drug is currently in Phase 3 clinical trials for various skin conditions outside China and has shown promising results in improving skin repigmentation. If approved, povorcitinib could enhance Dermavon’s product portfolio and provide comprehensive treatment options for vitiligo patients.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings Limited, along with its subsidiaries, operates in the pharmaceutical industry with a focus on innovative drug development, particularly in skin health. Its subsidiary, Dermavon Holdings Limited, specializes in skin-related treatments and is in the process of applying for an independent listing on the Hong Kong Stock Exchange.
YTD Price Performance: 84.90%
Average Trading Volume: 5,513,838
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.1B
For an in-depth examination of 0867 stock, go to TipRanks’ Overview page.